The Effects of Serum hs-CRP on the Incidence of Lung Cancer in Male Patients with Pulmonary Tuberculosis

  • Youhua JIANG Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou 310000, P.R. China
  • Kewei NI Department of Cardio-Thoracic Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310000, P.R. China
  • Meiyu FANG Department of Comprehensive Medical Oncology, Zhejiang Cancer Hospital, Hangzhou 310000, P.R. China
  • Junling LIU State Key Laboratory of Oncology in Southern China, Collaborative Innovation Center for Cancer Medicine, Department of Medi-cal Oncology, Sun Yat-sen University Cancer Centre, Guangzhou 510060, P.R. China
Keywords: Pulmonary tuberculosis, High-sensitivity C-reactive protein (hs-CRP), Lung cancer

Abstract

Background: This study intended to investigate the effects of serum high-sensitivity C-reactive protein (hs-CRP) on the incidence of lung cancer in male patients with pulmonary tuberculosis. Methods: A total of 1091 male patients with pulmonary tuberculosis in Zhejiang Cancer Hospital, Hangzhou, China from Jan 2009 to Jan 2012 were selected as the research objects. All patients were followed up from the beginning of hospitalization. According to serum hs-CRP level, patients were divided into two groups: group A (hs-CRP < 1 mg/L) and group B (hs-CRP > 3 mg/L). The relationship between baseline hs-CRP and the risk of lung cancer in patients with pulmonary tuberculosis was analyzed by multivariate Cox proportional risk regression model, and the serum levels of hs-CRP between lung cancer patients in all groups and other non-lung cancer patients were compared. Results: There were differences in age, drinking, smoking, diabetes history, body mass index (BMI), thyroglobulin (TG), history of hypertension and hyperglycemia among the three groups (P=0.036, 0.018, 0.040, 0.029, 0.006, 0.034, 0.020, 0.010). The serum levels of hs-CRP in patients with squamous carcinoma, adenocarcinoma and small cell carcinoma were significantly higher than those in non-lung cancer patients (P=0.022, 0.043, 0.011). The incidence rates of lung cancer in patients in group B and C were 1.37 and 1.69 times higher than that in group A, respectively. Conclusion: The increased serum level of hs-CRP will increase the incidence rate of lung cancer in male patients with pulmonary tuberculosis.    

References

1. Lee J, Tupasi, TE, Park YK (2014). Use of the VNTR typing technique to determine the origin of Mycobacterium tuberculosis strains isolated from Filipino patients in Korea. World J Microbiol Biotechnol, 30: 1625-1631.
2. Ang KC, Ibrahim P, Gam LH (2014). Anal-ysis of differentially expressed proteins in late-stationary growth phase of Mycobac-terium tuberculosis H37Rv. Biotechnol Appl Biochem, 61: 153-164.
3. Rybniker J, Pojer F, Marienhagen J, et al (2014). The cysteine desulfurase IscS of Mycobacterium tuberculosis is involved in iron sulfur cluster biogenesis and oxi-dative stress defence. Biochem J, 459: 467-478.
4. Singh S, Sarkar PD (2014). Serum lipids, tHcy, hs-CRP, MDA and PON-1 levels in SCH and overt hvpothyroidism: effect of treatment. Acta Biomed, 85: 127-134.
5. Simmons CP, Koinis F, Fallon MT, et al (2015). Prognosis in advanced lung can-cer - A prospective study examining key clinicopathological factors. Lung Cancer, 88: 304-309.
6. Kiyohara C, Horiuchi T, Takayama K, Nakanishi Y (2014). Genetic polymor-phisms involved in the inflammatory re-sponse and lung cancer risk: A case-control study in Japan. Cytokine, 65: 88-94.
7. Terata K, Motoyama S, Kamata S, et al (2014). Evaluation of the potential for lymph node metastasis using CRP 1846C>T genetic polymorphism in inva-sive breast cancer. Tumour Biol, 35: 5931-5935.
8. Zhou T, Hong S, Hu Z, et al (2015). A sys-temic inflammation-based prognostic scores (mGPS) predicts overall survival of patients with small-cell lung cancer. Tumour Biol, 36: 337-343.
9. Kathirvel M, Kommoju V, Brammacharry U, et al (2014). Clinical evaluation of mtp40 polymerase chain reaction for the diagnosis of extra pulmonary tuberculo-sis. World J Microbiol Biotechnol, 30: 1485-1490.
10. Uyanik V, Tuglu C, Gorgulu Y, Kunduracilar H, Uyanik MS (2015). Assessment of cy-tokine levels and hs-CRP in bipolar I disorder before and after treatment. Psy-chiatry Res, 228: 386-392.
11. Ganie MA, Hassan S, Nisar S, et al (2014). High-sensitivity C-reactive protein (hs-CRP) levels and its relationship with components of polycystic ovary syn-drome in Indian adolescent women with polycystic ovary syndrome (PCOS). Gyne-col Endocrinol, 30: 781-784.
12. Guo C, Zhang S, Zhang J, Liu H, Li P, Liu H, Wang Y (2014). Correlation between the severity of coronary artery lesions and levels of estrogen, hs-CRP and MMP-9. Exp Ther Med, 7: 1177-1180.
13. Ajmal MR, Yaccha M, Malik MA, et al (2014). Prevalence of nonalcoholic fatty liver disease (NAFLD) in patients of car-diovascular diseases and its association with hs-CRP and TNF-alpha. Indian Heart J, 66: 574-579.
14. Cho SY, You E, Lee HJ, et al (2014). Mean platelet volume shows a significant posi-tive correlation with hs-CRP in Korean patients with various disease conditions. Clin Lab, 60: 1775-1777.
15. Song IU, Cho HJ, Kim JS, et al (2014). Se-rum hs-CRP Levels are increased in de Novo Parkinson's Disease Independently from Age of Onset. Eur Neurol, 72: 285-289.
Published
2019-07-01
How to Cite
1.
JIANG Y, NI K, FANG M, LIU J. The Effects of Serum hs-CRP on the Incidence of Lung Cancer in Male Patients with Pulmonary Tuberculosis. Iran J Public Health. 48(7):1265-1269.
Section
Original Article(s)